Centrexion Therapeutics changes its mind on initial public offering
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.